Renal lithiasis Urological and Genital Diseases Calculus of kidney and ureter
Conditions
Interventions
Coenzyme Q10 is administered (two 30 mg capsules every 8 hours) for 14 days versus placebo.
Sponsors
Association of Urology Research and Development (Asociacion de Urologia y Desarrollo de la Investigacion) (Spain)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Adult patients aged 25 to 65 years (either sex) with urinary tract lithiasis 2. Candidates to applying lithotripsy 3. Lithiasis located in the renal pelvis and/or calyx
Exclusion criteria
Exclusion criteria: 1. Patients undergoing lithotripsy at the time of initiating the study 2. Patients with previously diagnosed renal lithotripsy 3. Patients treated with calcium channel blockers 4. Complications of lithotripsy that determine the need for further intervention in the study period 5. Taking antiplatelet 3 days before extracorporeal shock-wave lithotripsy (ESWL) session 6. Controlled clotting disorders 7. Complete distal obstruction to the calculation to be treated 8. Unrecovery kidney 9. Allergy to the components of medications 10. Inability to understand or psychosocial misadjustment 11. Refusal to sign informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determination of glomerular filtration rate (MDRD), measured in June 2010 and September 2010 | — |
Secondary
| Measure | Time frame |
|---|---|
| Measured in June 2010 and September 2010: 1. Biochemical markers of oxidative stress: 1.1. MDA 1.2. Glutation 1.3. SOD 1.4. Catalase | — |
Countries
Spain
Outcome results
None listed